Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible ...

The US Food and Drug Administration (FDA) has approved Boston Scientific’s expanded instructions for use (IFU) labelling of ...

Marlborough: Boston Scientific Corporation has announced that the company has received approval from the U.S. Food and Drug ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the ...

Boston Scientific (NYSE: BSX) announced that the FDA approved an expansion to the label of its Farapulse pulsed field ...

Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, ...

Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...

Boston Scientific reported that electrophysiology sales grew 172% in Q4 2024, driven by an uptake of its Farapulse pulsed ...

New Strategic Investments to Drive Electrophysiology: Following the acquisitions of Farapulse and Baylis Medical in 2022, Boston Scientific’s EP business is rapidly growing in market share globally.

Boston Scientific plucked Farapulse from its own venture capital portfolio. With its venture capital arm, the firm makes small bets on younger companies — it has about 40 investments today ...